anti-CD16/anti-NKp46/anti-CD19 trispecific NK-cell engager (Innate Pharma)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD16/anti-NKp46/anti-CD19 trispecific NK-cell engager (Innate Pharma)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsNatural cytotoxicity triggering receptor 1 modulatorsLow affinity immunoglobulin gamma Fc region receptor III agonists

TargetsB-lymphocyte antigen CD19Natural cytotoxicity triggering receptor 1Low affinity immunoglobulin gamma Fc region receptor III

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesInnate Pharma SA

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesInnate Pharma SA

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A